Thursday, March 07, 2019 11:23:59 AM
This time, with a design freeze, is a much clearer message to the market that there not only will not be a delay, but also likely even better pre-clinical results with improvements.
The first pre-clinical studies will immediately follow design freeze. So it stands to reason that we will climb into that range 10-15 fairly quickly (by the fall) following an initial bump in PPS with design freeze (early summer). My guess is 6-8 early summer.
We'd want that to happen, to have the 40 million in warrants for Q3 and Q4, and a bit beyond. Otherwise, yet another financing (but it is becoming less and less relevant). Things are pretty bright at this point as is.
End of year, anything is possible with successful human trials and FDA submission as far as PPS. That will give us some wild press...tummies with no scars....road shows as we wait for FDA approval...and some real initial serious interest from acquirers..
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM